PMID- 27047280
OWN - NLM
STAT- MEDLINE
DCOM- 20170109
LR  - 20181113
IS  - 1526-6702 (Electronic)
IS  - 0730-2347 (Print)
IS  - 0730-2347 (Linking)
VI  - 43
IP  - 1
DP  - 2016 Feb
TI  - The Mosaic Mitral Valve Bioprosthesis: A Long-Term Clinical and Hemodynamic 
      Follow-Up.
PG  - 13-9
LID - 10.14503/THIJ-14-4407 [doi]
AB  - We reviewed the cases of 100 patients (mean age, 73 +/- 10 yr; 64 men) who had 
      mitral valve replacement with a Medtronic Mosaic porcine bioprosthesis from 1995 
      through 2011. The mean New York Heart Association (NYHA) class was 3 +/- 0.7, and 
      52 patients were in atrial fibrillation. Prosthetic sizes were chiefly 27 mm (50 
      patients) and 29 mm (40 patients). Follow-up ended in December 2012 and is 97% 
      complete, with a cumulative duration of 611 patient-years (mean duration, 6 +/- 4.6 
      yr; maximum, 17.7 yr). The early mortality rate was 10% (6% in elective 
      patients); late deaths occurred in 31 patients (5 valve-related). Actuarial 
      survival rates at 5, 10, and 15 years were 74% +/- 5%, 50% +/- 6%, and 37% +/- 8%. The 
      mean NYHA class in survivors was 1.4 +/- 0.6 (P <0.0001). Thromboembolic episodes 
      occurred in 4 patients, with an actuarial freedom at 15 years of 91% +/- 5%. No 
      cases of endocarditis were observed. Four patients needed reoperation, 2 for 
      structural failure, and 1 each for perivalvular leakage and valve thrombosis. 
      Actuarial freedom from structural failure and from reoperation, respectively, was 
      93% +/- 5% and 91% +/- 5% at 15 years. Echocardiographic follow-up in 24 patients 
      with 27-mm prostheses showed a mean gradient of 5 +/- 1.7 mmHg and an effective 
      orifice area of 1.57 +/- 0.3 cm(2); in 16 patients with 29-mm prostheses, the mean 
      gradient was 4.5 +/- 1.9 mmHg, and the effective orifice area, 1.63 +/- 0.4 cm(2). 
      During nearly 17 years of follow-up, the Mosaic bioprosthesis has shown good 
      overall clinical and hemodynamic performance after mitral valve replacement.
FAU - Celiento, Michele
AU  - Celiento M
FAU - Blasi, Stefania
AU  - Blasi S
FAU - De Martino, Andrea
AU  - De Martino A
FAU - Pratali, Stefano
AU  - Pratali S
FAU - Milano, Aldo D
AU  - Milano AD
FAU - Bortolotti, Uberto
AU  - Bortolotti U
LA  - eng
PT  - Journal Article
DEP - 20160201
PL  - United States
TA  - Tex Heart Inst J
JT  - Texas Heart Institute journal
JID - 8214622
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Animals
MH  - *Bioprosthesis
MH  - Echocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Valve Diseases/diagnosis/physiopathology/*surgery
MH  - Hemodynamics/*physiology
MH  - Humans
MH  - Incidence
MH  - Italy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve/diagnostic imaging/*surgery
MH  - Postoperative Complications/*epidemiology
MH  - Prognosis
MH  - Prosthesis Design
MH  - Retrospective Studies
MH  - Survival Rate/trends
MH  - Swine
MH  - Time Factors
PMC - PMC4810578
OTO - NOTNLM
OT  - Bioprosthesis
OT  - calcinosis/prevention & control
OT  - heart valve prosthesis
OT  - mitral valve replacement
OT  - mitral valve/surgery
OT  - oleic acids/therapeutic use
OT  - retrospective studies
OT  - thromboembolism
EDAT- 2016/04/06 06:00
MHDA- 2017/01/10 06:00
PMCR- 2016/02/01
CRDT- 2016/04/06 06:00
PHST- 2016/04/06 06:00 [entrez]
PHST- 2016/04/06 06:00 [pubmed]
PHST- 2017/01/10 06:00 [medline]
PHST- 2016/02/01 00:00 [pmc-release]
AID - 10.14503/THIJ-14-4407 [doi]
PST - epublish
SO  - Tex Heart Inst J. 2016 Feb 1;43(1):13-9. doi: 10.14503/THIJ-14-4407. eCollection 
      2016 Feb.